Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

NCT01426009 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: EP-101 via nebulizer (eFlow®) 25 ug
DRUG: EP-101 via nebulizer (eFlow®) 50 ug
DRUG: EP-101 via nebulizer (eFlow®) 100 ug
DRUG: Placebo EP-101
DRUG: Tiotropium bromide via (Spiriva® Handihaler®)
DRUG: Ipratropium bromide Inhalation Solution via Handihaler® DPI
DRUG: EP-101 via nebulizer (eFlow®) 200 ug

Sponsor

Sunovion Respiratory Development Inc.